Effect of ONO-4641, a potent, oral, selective sphingosine-1-phosphate receptor-1 and-5 agonist, on MRI outcomes in patients with relapsing remitting multiple sclerosis: Subgroup analyses from the phase 2 DreaMS study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2013
This article has no abstract
Epistemonikos ID: 208f92c9b107b715ccf83376b62a52ad34b7d890
First added on: Apr 30, 2026